DETAILED NOTES ON LINK ALTERNATIF MBL77

102 On the flip side, a number of teams are advocating for the incorporation of novel markers, such as a complex karyotype55 or epigenetic subsets, 27,28 into clinical practice. These novel prognostic and/or predictive types will should be validated in cohorts of sufferers treated with focused agents.Some degree of immunophenotype overlap amid CLL,